BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1340 related articles for article (PubMed ID: 33003377)

  • 1. Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19.
    McGowan EM; Haddadi N; Nassif NT; Lin Y
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Infection: A Role for S1P/S1P Receptor Signaling in the Nervous System?
    Meacci E; Garcia-Gil M; Pierucci F
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32942748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Battling COVID-19 Pandemic: Sphingosine-1-Phosphate Analogs as an Adjunctive Therapy?
    Naz F; Arish M
    Front Immunol; 2020; 11():1102. PubMed ID: 32670273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the SphK-S1P-S1PRs pathway in invasion of the nervous system by SARS-CoV-2 infection.
    Pan Y; Gao F; Zhao S; Han J; Chen F
    Clin Exp Pharmacol Physiol; 2021 May; 48(5):637-650. PubMed ID: 33565127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
    Santos J; Brierley S; Gandhi MJ; Cohen MA; Moschella PC; Declan ABL
    Viruses; 2020 Jun; 12(7):. PubMed ID: 32629804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer.
    Barbieri A; Robinson N; Palma G; Maurea N; Desiderio V; Botti G
    Front Immunol; 2020; 11():588724. PubMed ID: 33117402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19.
    Saul S; Einav S
    ACS Infect Dis; 2020 Sep; 6(9):2304-2318. PubMed ID: 32687696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
    Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK
    Front Immunol; 2020; 11():1880. PubMed ID: 32973779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
    Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding COVID-19: From Origin to Potential Therapeutics.
    Moazzam M; Sajid MI; Shahid H; Butt J; Bashir I; Jamshaid M; Shirazi AN; Tiwari RK
    Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32823901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
    Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
    Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the
    López-Iranzo FJ; López-Rodas AM; Franco L; López-Rodas G
    Curr Pharm Des; 2020; 26(35):4515-4521. PubMed ID: 32787748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms Underlying Potential Therapeutic Approaches for COVID-19.
    Benani A; Ben Mkaddem S
    Front Immunol; 2020; 11():1841. PubMed ID: 32793246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Human Respiratory Epithelium.
    Milewska A; Kula-Pacurar A; Wadas J; Suder A; Szczepanski A; Dabrowska A; Owczarek K; Marcello A; Ochman M; Stacel T; Rajfur Z; Sanak M; Labaj P; Branicki W; Pyrc K
    J Virol; 2020 Jul; 94(15):. PubMed ID: 32434888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of epigenomic networks entailed in coronavirus infections and COVID-19.
    El Baba R; Herbein G
    Clin Epigenetics; 2020 Aug; 12(1):118. PubMed ID: 32758273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19: a conundrum to decipher.
    Deshmukh V; Tripathi SC; Pandey A; Deshmukh V; Vykoukal J; Patil A; Sontakke B
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5830-5841. PubMed ID: 32495923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory Drugs in the Management of SARS-CoV-2.
    Burrage DR; Koushesh S; Sofat N
    Front Immunol; 2020; 11():1844. PubMed ID: 32903555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.
    Clementi N; Ferrarese R; Criscuolo E; Diotti RA; Castelli M; Scagnolari C; Burioni R; Antonelli G; Clementi M; Mancini N
    J Infect Dis; 2020 Aug; 222(5):722-725. PubMed ID: 32559285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment Option for COVID-19.
    Hassan STS
    Viruses; 2020 Apr; 12(4):. PubMed ID: 32340120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.